Skip to main content

Table 1 Patient demographics and clinical characteristics (ITT-population: n = 77)

From: Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience

 

Overall

Starting dose

Starting dose

320 mg/m2

≤280 mg/m2

 

n = 77

n = 37

n = 40 *

Female

14 (18.2 %)

6 (16.2 %)

8 (20.0 %)

Male

63 (81.1 %)

31 (83.3 %)

32 (80.0 %)

Median age in years (range)

67 (39–80)

66 (39–77)

70 (51–80)

≥70 y

32 (41.6 %)

12 (32.4 %)

20 (50.0 %)

ECOG PS

   

0

35 (45.5 %)

18 (48.6 %)

17 (42.5 %)

1

42 (54.5 %)

19 (51.4 %)

23 (57.5 %)

Visceral involvement

46 (59.7 %)

23 (62.2 %)

23 (57.5 %)

Liver metastases†

17 (22.1 %)

6 (16.2 %)

11 (27.5 %)

TFPC < 6 months‡

45 (58.4 %)

19 (51.4 %)

26 (65.0 %)

Mean Hb in g/dL§

11.2

11.6

10.9

Hb < 10 g/dL§

13 (16.9 %)

5 (13.5 %)

8 (20.0 %)

  1. ECOG: Eastern Cooperative Oncology Group; PS: performance status; TFPC: time from prior chemotherapy; Hb: hemoglobin
  2. *n(280 mg/m2) = 30; n(<280 mg/m2) = 10
  3. †information missing for 4 patients in the 320 mg/m2 group and 8 patients in the ≤ 280 mg/m2 group
  4. ‡information missing for 6 patients in the 320 mg/m2 group and 2 patients in the ≤ 280 mg/m2 group
  5. §information missing for 6 patients in the 320 mg/m2 group and 2 patients in the ≤ 280 mg/m2 group; ITT: intent-to-treat
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us